Xtant Medical (NYSEAMERICAN:XTNT) Issues Earnings Results

Posted by Brian Himes on May 13th, 2026

Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) issued its quarterly earnings data on Wednesday. The medical device company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02), FiscalAI reports. Xtant Medical had a return on equity of 10.27% and a net margin of 3.71%.The company had revenue of $20.88 million during the quarter, compared to analysts’ expectations of $20.16 million.

Here are the key takeaways from Xtant Medical’s conference call:

Xtant raised its full-year 2026 revenue guidance to $101 million to $105 million, citing the addition of HEMOBLAST, recent product launches, and expanded sales coverage.
The company secured exclusive U.S. distribution rights to HEMOBLAST Bellows, giving it entry into an estimated $2 billion hemostatic products market and broadening its biologics portfolio.
Proceeds from the Companion Spine divestiture were used to strengthen the balance sheet, with Xtant reducing total indebtedness by $13.3 million in the quarter and increasing revolver availability.
First-quarter revenue was $20.9 million, down from the prior-year period on a pro forma basis, mainly due to headwinds in amnio products tied to the advanced wound care market and the loss of non-recurring license revenue.
Gross margin fell to 57.3% from 61.5% last year, and the company said the decline reflected the end of Q-code license revenue plus some product-mix pressure and excess inventory charges.

Xtant Medical Price Performance

XTNT stock traded down $0.02 on Wednesday, reaching $0.48. 270,256 shares of the company’s stock were exchanged, compared to its average volume of 158,929. The stock has a fifty day moving average of $0.55 and a 200-day moving average of $0.64. Xtant Medical has a twelve month low of $0.44 and a twelve month high of $0.95. The firm has a market cap of $67.21 million, a PE ratio of 16.00 and a beta of -0.11. The company has a quick ratio of 1.63, a current ratio of 2.65 and a debt-to-equity ratio of 0.22.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on XTNT shares. Craig Hallum restated a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. BTIG Research restated a “buy” rating and set a $1.00 price target on shares of Xtant Medical in a research note on Wednesday. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $1.00.

View Our Latest Analysis on XTNT

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in Xtant Medical during the second quarter worth $26,000. Mink Brook Asset Management LLC increased its position in shares of Xtant Medical by 125.8% in the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. Wiregrass Investment Management LLC purchased a new position in shares of Xtant Medical in the fourth quarter valued at $81,000. Nantahala Capital Management LLC increased its position in shares of Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company’s stock valued at $50,543,000 after buying an additional 57,000,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Xtant Medical by 4.6% in the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock valued at $1,529,000 after buying an additional 104,159 shares in the last quarter. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Company Profile

(Get Free Report)

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.